Self-assembled polypeptide nano-drug and application thereof

By designing self-assembled peptide nanomedicine NF-H to mimic the function of FGF10, the stability and cost issues of recombinant proteins in the treatment of photodamage to the skin were solved, achieving highly efficient skin repair and regeneration effects.

CN120899880APending Publication Date: 2025-11-07THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511087286.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-05
Publication Date
2025-11-07

AI Technical Summary

Technical Problem

The existing recombinant protein FGF10 has a short half-life, is easily inactivated, and has high production costs, which limits its widespread clinical application in the treatment of photodamage to the skin.

Method used

We developed a self-assembled peptide nanomedicine, NF-H, which specifically binds to FGFR2b by mimicking the function of FGF10, promoting keratinocyte proliferation and migration, reducing UVB-induced apoptosis, oxidative stress and inflammation, and promoting skin repair.

Benefits of technology

NF-H significantly improves the repair effect of skin photodamage, enhances stability and bioactivity, promotes wound healing, reduces the expression of inflammatory factors, improves skin appearance and restores collagen.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120899880A_ABST
    Figure CN120899880A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to a self-assembled polypeptide nano-drug and application thereof. The assembled polypeptide nano drug is Nap-FFGHLQGDVRWRKLFS, and is characterized in that the assembled polypeptide nano drug is Nap- The self-assembled polypeptide nano-drug (NF-H) has higher binding affinity, and can effectively promote proliferation and migration of human keratinocytes. In addition, NF-H shows a remarkable effect of promoting light-damaged skin repair, and it is proved that the wound healing rate in a light-damaged mouse model is increased. The discoveries prove that the self-assembled polypeptide nano-drug simulating the FGF10 function has the potential in the aspect of treating the skin light injury.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medicine, in particular to a self-assembled polypeptide nanodrug and application thereof. BACKGROUND

[0002] Skin, as the largest organ of the human body, is a key barrier to resist external pathogens and environmental factors. Acute UV radiation exposure can cause damage to the skin barrier system, triggering a series of pathophysiological changes, including erythema, sunburn, increased vascular permeability and edema, etc. At the cellular level, epidermal keratinocytes will exhibit inflammation, oxidative stress, DNA damage and apoptosis, etc. According to research, FGF10 can stimulate keratinocyte proliferation and migration in the epidermis, and is involved in the regulation of cell cycle, DNA repair, apoptosis and wound healing, etc. Previous studies have confirmed that FGF10 is a key factor in mediating the response of tissues and cells to UVB. Based on the regulatory role of FGF10 in the epidermis, its application in the treatment of skin photodamage has broad prospects. The currently used exogenous FGF10 is mainly recombinant protein, which has the limitations of short half-life, easy inactivation and degradation, high production cost, strict storage and transportation conditions, etc., which seriously hinder its wide clinical application. Therefore, it is urgent to develop a substitute for FGF10. SUMMARY

[0003] To solve the above problems, the present application provides a self-assembled polypeptide nanodrug and application thereof. The self-assembled polypeptide nanodrug (NF-H) has higher binding affinity and can effectively promote human keratinocyte proliferation and migration. In addition, NF-H shows a significant effect of promoting the repair of photodamaged skin, and the increased wound healing rate in a photodamaged mouse model proves this. These findings demonstrate the potential of self-assembled polypeptide nanodrug mimicking the function of FGF10 in the treatment of skin photodamage.

[0004] To achieve the above purpose, the present application provides the following technical solutions:

[0005] The present application provides a self-assembled polypeptide nanodrug, which is Nap-FFGHLQGDVRWRKLFS.

[0006] The present application also provides the application of the self-assembled polypeptide nanodrug in the preparation of a product specifically binding to FGFR2b.

[0007] The present application also provides the application of the self-assembled polypeptide nanodrug in the preparation of a product promoting human keratinocyte proliferation.

[0008] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for reducing UVB-induced cell ROS increase.

[0009] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for reducing UVB-induced cell apoptosis.

[0010] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for reducing UVB-induced cell inflammation level.

[0011] Preferably, the inflammation factors of cell inflammation include IL-1β, IL-6 and TNF-α.

[0012] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for promoting recovery of light-damaged skin.

[0013] Beneficial effects:

[0014] The application analyzes the binding sites of FGF10, FGFR2b and heparin in detail. Through systematic screening, the key sequence HLQGDVRWRKLFS (72-84) is identified. The sequence can not only specifically bind to FGFR2b, but also is one of the important heparin binding sites. Then, by introducing the self-assembling sequence Nap-FFG, the application constructs a polypeptide self-assembling supramolecular nanomaterial simulating the function of FGF10, and is named as NF-H. In vivo and in vitro experiments show that NF-H can well bind to FGFR2b, effectively induce phosphorylation of FGFR2b, activate downstream signal transduction, and promote HaCaT cell proliferation, effectively reduce UVB-induced cell apoptosis, DNA damage and oxidative stress. At the same time, in the UVB-induced light-damaged mouse model, local application of NF-H can significantly improve the appearance of the skin, reduce epidermal thickening, promote collagen recovery, and reduce the expression of inflammatory factors in the tissue.

[0015] In summary, the application successfully develops a self-assembling nanodrug NF-H simulating the function of FGF10, which exhibits better stability and comparable biological activity than natural FGF10, and shows significant light-damage protection and repair effects in in vivo and in vitro experiments. This design of simulating the specific binding of a protein or factor to a corresponding receptor to play a biological function after regulating the function in the tissue is an important way in disease treatment. The NF-H designed by this concept provides an innovative and feasible solution for treating UV-induced skin light damage. At the same time, it can also further expand its application in the field of tissue and organ repair and regeneration. BRIEF DESCRIPTION OF DRAWINGS

[0016] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the drawings required by the embodiments will be briefly introduced.

[0017] Figure 1 MS spectrum of NF-H;

[0018] Figure 2 MS spectrum of NF;

[0019] Figure 3 MS spectrum of H;

[0020] Figure 4 MS spectrum of NF-G;

[0021] Figure 5 Electron microscope image of H and NF-H (left), CMC determination of H and NF-H (right);

[0022] Figure 6 Optical image of H and NF-H;

[0023] Figure 7 A and B are binding sites of H; C and D are binding sites of NF-H;

[0024] Figure 8 Binding affinity of H and NF-H to FGFR2b;

[0025] Figure 9 NF-H can resist protease degradation;

[0026] Figure 10 NF-H can effectively promote Hacat cell proliferation;

[0027] Figure 11 NF-H can activate FGFR2b and its substrate phosphorylation;

[0028] Figure 12 NF-H can resist cell viability decline and ROS level rise;

[0029] Figure 13 NF-H can resist UVB-induced apoptosis;

[0030] Figure 14 NF-H can reduce UVB-induced cell inflammation level;

[0031] Figure 15 NF-H can significantly promote photodamaged skin recovery in vivo. DETAILED DESCRIPTION

[0032] The application provides a self-assembled polypeptide nanodrug, the self-assembled polypeptide nanodrug is Nap-FFGHLQGDVRWRKLFS (SEQ ID No. 1), hereinafter referred to as NF-H, and the NF-H comprises two parts: an element Nap-FFG (referred to as NF) with a self-assembly function and a polypeptide HLQGDVRWRKLFS (referred to as H) with a function of simulating FGF10. The application does not have special limitation on the preparation method of the self-assembled polypeptide nanodrug, and the self-assembled polypeptide nanodrug can be prepared by using a conventional preparation method. The application also discloses NF-G (Nap-FFGGWKQDLSLVRRHF) (SEQ ID No. 2). In the application, the structures of the self-assembled polypeptide nanodrug, NF, H and NF-G are as follows:

[0033]

[0034] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for specifically combining with FGFR2b.

[0035] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for promoting proliferation of human keratinocytes.

[0036] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for reducing UVB-induced increase of ROS of cells.

[0037] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for reducing UVB-induced apoptosis of cells.

[0038] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for reducing UVB-induced inflammation level of cells. In the application, the inflammatory factors of the cell inflammation include IL-1β, IL-6 and TNF-α. The application does not have special limitation on the type of the product.

[0039] The application also provides application of the self-assembled polypeptide nanodrug in preparation of a product for promoting recovery of light-damaged skin.

[0040] In order to further illustrate the application, the application is described in detail in combination with examples below, but they should not be understood as limitation on the protection scope of the application.

[0041] Example 1

[0042] 1. Materials and General Methods

[0043] Dichloromethane resin (1.1 mmol / g), Fmoc protected amino acids, peptide coupling reagent HBTU were purchased from Shanghai Gile Biochemical Co. Ltd.

[0044] 2. Synthesis of Compounds

[0045] The specific steps are as follows:

[0046] 1) 0.5 mmol 2-cl-Trt resin was weighed in a solid phase synthesizer, 10 mL of anhydrous dichloromethane (hereinafter referred to as DCM) was added, and the 2-Cl-Trt resin was fully swelled by placing it on a shaker for 5 min;

[0047] 2) The DCM was completely removed from the solid phase synthesizer containing the 2-Cl-Trt resin using a wash ball;

[0048] 3) 0.75 mmol of Fmoc protected amino acid was dissolved in 10 mL of anhydrous DCM, 0.75 mmol of DIEPA was added, and then transferred to the above-mentioned solid phase synthesizer, and 0.75 mmol of DIEPA was added, and reacted at room temperature for 1 h;

[0049] 4) Capping: the reaction solution in the solid phase synthesizer was removed using a wash ball, and then washed with 10 mL of anhydrous DCM for 1 min each time, a total of 5 times, and a solution of anhydrous DCM:DIEPA:methanol in a volume ratio of 17:1:2 was added in a volume of 20 mL, and reacted at room temperature for 10 min;

[0050] 5) The reaction solution in the solid phase synthesizer was removed using a wash ball, first washed with anhydrous DCM, 10 mL of DCM was used each time, and the washing time was 1 min, a total of 5 times, then washed with N,N-dimethylformamide (hereinafter referred to as DMF), 10 mL of DMF was used each time, and the washing time was 1 min, a total of 5 times, 10 mL of DMF containing 20% by volume of piperidine was added, reacted for 25 min, then 10 mL of DMF containing 20% by volume of piperidine was added, reacted for 5 min, then washed with DMF, 10 mL of DMF was used each time, and the washing time was 1 min, a total of 5 times, and the next step was carried out;

[0051] 6) 1 mmol of the second Fmoc protected amino acid, 1.5 mmol of HBTU, 2 mmol of DIEPA and 10 mL of DMF were added, and the prepared solution was added to the above-mentioned solid phase synthesizer, and reacted for 2 h;

[0052] 7) Repeat the method of step 5) and 6) to add the desired amino acid or capping group HCPT-SA in turn; then wash with DMF 5 times, dichloromethane 5 times, and proceed to the next step of reaction;

[0053] 8) 10 mL of 95% TFA, 2.5% TIS, 2.5% H2O by volume was added to the above-mentioned solid phase synthesizer, and the reaction was carried out for half an hour. The product was cut off from the 2-cl-Trt resin, vacuum concentrated, and the solvent was removed to obtain a crude product, which was then separated and purified by HPLC to obtain Nap-FFGHLQGDVRWRKLFS, HLQGDVRWRKLFS, Nap-FFG, Nap-FFGGWKQDLSLVRRHF.

[0054] Example 2

[0055] 1. Self-assembly ability of H and NF-H: (1) Weigh 4 mg of the compound in a 2 mL glass bottle, and add 1 mL of PBS buffer with a pipette. Hold the bottle with tweezers and heat it on an alcohol lamp until the compound is completely dissolved, then place it on the experimental table to cool to room temperature. No visible light path is formed by H, but a stable light path is formed by NF-H; (2) After uranyl acetate staining, it can be seen from the electron microscope that H does not form fibers, while NF-H forms a large number of nanofibers, indicating the formation of self-assembly; (3) Dilute a series of concentration gradient samples with filtered PBS buffer, and take 100 μL of each sample and add it to the sample tank for detection of light intensity value in the dynamic light scattering instrument. It can be seen that H cannot be assembled into nanofibers, while NF-H can be assembled into nanofibers.

[0056] From Figure 5 and 6 It can be seen from the transmission electron microscope and the critical aggregation concentration experiment that H cannot be assembled into nanofibers, while NF-H can be assembled into nanofibers.

[0057] 2. Binding mode of H, NF-H and FGFR2b

[0058] From Figure 7 It can be seen from the computer simulation of molecular dynamics that the binding sites of H, NF-H and FGFR2b can be obtained.

[0059] 3. Binding ability of H and NF-H to FGFR2b

[0060] From Figure 8 It can be seen from the micro-thermal surge experiment (MST) that the binding affinity of H and NF-H to FGFR2b is determined. The results show that the binding affinity of the modified NF-H is significantly improved.

[0061] 4. NF-H can effectively resist degradation by proteases

[0062] from Figure 9 As can be seen, after co-incubation with trypsin, approximately 50% of NF-H remained after 4 hours, and approximately 30% remained after 24 hours. This indicates that NF-H has better stability.

[0063] 5. NF-H can promote the proliferation of human keratinocytes (Hacat).

[0064] from Figure 10 As can be seen from the CCK-8 and Edu proliferation experiments, after NF-H treatment, the Hacat cell viability was significantly increased and comparable to that of FGF10 protein, indicating that NF-H can significantly promote the proliferation of Hacat.

[0065] 6. NF-H can activate the phosphorylation of FGFR2b and its substrates.

[0066] from Figure 11 As can be seen from the results, the activation level of NF-H on FGFR2b and its substrate was detected by Western blotting. The results show that it can promote receptor phosphorylation and exert biological functions. This demonstrates that NF-H can not only bind tightly to FGFR2b, but also activate it to exert its efficacy.

[0067] 7. NF-H can resist UVB-induced decrease in cell viability and increase in ROS levels.

[0068] from Figure 12 As can be seen from the flow cytometry results, NF-H reduced the UVB-induced increase in cellular ROS levels.

[0069] 8. NF-H can resist UVB-induced apoptosis.

[0070] from Figure 13 As can be seen from the flow cytometry results, NF-H reduced UVB-induced apoptosis.

[0071] 9. NF-H can reduce UVB-induced cellular inflammation levels.

[0072] from Figure 14 As can be seen from the results, the levels of intracellular inflammatory factors were detected by the ELISA kit, and the results showed that NF-H could significantly reduce the levels of IL-1β, IL-6 and TNF-α.

[0073] 10. NF-H significantly promotes the recovery of photodamaged skin in vivo.

[0074] from Figure 15As can be seen, after the mouse model of light damage is constructed, the NF-H is applied to treat the same. The results show that the NF-H can significantly promote the recovery of skin damage and is close to healthy skin compared with the control group. The H&E and Masson staining results also show that the NF-H can reduce the thickness of the epidermis and promote the deposition of collagen fibers. The above results prove that the NF-H has good treatment potential for the light damage of the skin.

[0075] Although the above embodiment has made a detailed description of the present application, it is only a part of the embodiments of the present application, not all the embodiments, and other embodiments can be obtained according to the present embodiment without creativity, which all belong to the protection scope of the present application.

Claims

1. A self-assembling polypeptide nanomedicine, characterized in that, The assembled polypeptide nanodrug is Nap-FFGHLQGDVRWRKLFS.

2. Use of the self-assembled polypeptide nanodrug of claim 1 in the preparation of a product that specifically binds FGFR2b.

3. Use of the self-assembled polypeptide nanodrug of claim 1 in the preparation of a product that promotes human keratinocyte proliferation.

4. Use of the self-assembled polypeptide nanodrug of claim 1 in the preparation of a product that reduces UVB-induced cell ROS elevation.

5. Use of the self-assembled polypeptide nanodrug of claim 1 in the preparation of a product that reduces UVB-induced cell apoptosis.

6. Use of the self-assembled polypeptide nanodrug of claim 1 in the preparation of a product that reduces UVB-induced cell inflammation level.

7. Use according to claim 6, characterized in that, The inflammatory factors of the cell inflammation include IL-1β, IL-6, and TNF-α.

8. Use of the self-assembled polypeptide nanodrug of claim 1 in the preparation of a product that promotes photodamaged skin recovery.